SLC5A2 and myocardial infarction: Overall, SGLT2 inhibitor treatment, as compared with placebo, significantly reduced myocardial infarct size (SMD = −1.30 [95% CI −1.79, −0.81], Z = −5.20, p < 0.00001) (Fig. 3), referring to a mean 33% (95% CI 20%, 47%) difference in ratios.